Gyre Therapeutics (GYRE) Work In Process (2022 - 2026)

Gyre Therapeutics (GYRE) has 5 years of Work In Process data on file, last reported at $6.0 million in Q1 2026.

• Work In Process for Q1 2026 came in at $6.0 million, up 74.82% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.0 million (up 74.82% YoY), and the FY2025 annual result was $6.3 million, up 115.33% from the prior year.
• Work In Process declined to $6.0 million in Q1 2026 per GYRE's latest filing, from $6.3 million in the prior quarter.
• Over five years, Work In Process peaked at $6.3 million in Q4 2025 and troughed at $2.0 million in Q4 2023.
• A 5-year average of $3.8 million and a median of $3.5 million in 2024 frame the typical range for Work In Process.
• The sharpest annual moves came in 2023 and 2025: Work In Process sank 45.54% in 2023, then soared 115.33% in 2025.
• A 5-year view of Work In Process shows it stood at $3.7 million in 2022, then slumped by 45.54% to $2.0 million in 2023, then surged by 46.67% to $2.9 million in 2024, then soared by 115.33% to $6.3 million in 2025, then retreated by 4.98% to $6.0 million in 2026.
• Business Quant data shows GYRE's Work In Process at $6.0 million in Q1 2026, $6.3 million in Q4 2025, and $4.4 million in Q3 2025.